---
schema_version: "secwatch.filing_event.v1"
accession: "0001618835-23-000018"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-03-21T23:59:59+00:00"
generated_at: "2026-06-17T22:15:58.675277+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evofem reduces workforce 39%, cuts CEO pay 40% to reach cash flow breakeven by year-end 2023

## Summary
- 39% reduction in payroll expenses via salary cuts, elimination of 8 positions including Chief Commercial Officer.
- CEO base salary reduced by 40% to ~$520K for remainder of FY 2023; other execs cut 20% vs prior year.
- Annualized cost savings of ~$4.3M; one-time pre-tax charges of ~$0.1M for severance and benefits.
- Three sales territories consolidated; RIF expected to be substantially complete by Q1 2023.
- Goal to reach cash flow break even by year-end 2023; company cites need to preserve capital.

## SEC filing metadata
- accession: 0001618835-23-000018
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000018/0001618835-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000018/evfm-20230317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001618835-23-000018
- JSON: https://secwatch.observer/filing/0001618835-23-000018.json
- Plain text: https://secwatch.observer/filing/0001618835-23-000018.txt

## Key facts
- Executive change
  Katherine Atkinson was terminated as Chief Commercial Officer at Evofem Biosciences, Inc..
  - Action: terminated
  - Role: Chief Commercial Officer
  source text: In connection with the RIF, the Company terminated the employment of Katherine Atkinson as the Company’s Chief Commercial Officer, effective March 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000018/0001618835-23-000018-index.htm
- Restructurings & Charges
  Evofem Biosciences, Inc. announced a restructuring with charges of aggregate pre-tax charges of approximately $0.1 million in connection with the reduction in force, primarily consisting of notice period and severance payments, affecting Company-wide (office and management positions) (39% reduction of payroll expenses; elimination of eight office and management positions including Chief Commercial Offic).
  - Type: restructuring
  - Charge: aggregate pre-tax charges of approximately $0.1 million in connection with the reduction in force, primarily consisting of notice period and severance payments,
  - Affected area: Company-wide (office and management positions)
  - Headcount: 39% reduction of payroll expenses; elimination of eight office and management positions including Chief Commercial Offic
  source text: On March 20, 2023 the Board of Directors of Evofem Biosciences, Inc. (the “Company”) approved a reduction in force (“RIF”) intended to conserve the Company’s current cash resources and manage operating expenses. The Company will reduce its current workforce resulting in an overall 39% reduction of payroll expenses including (i) salary cuts for certain employees, (ii) elimination of eight office and management positions including the elimination of the Chief Commercial Officer role effective March 17, 2023; and (iii) reduction of the Chief Executive Officer’s salary by 40%. The Company expects annualized future cost savings from the reduction in force to be approximately $4.3 million, which the Company intends to use to support its operations. The Company estimates that it will incur aggregate pre-tax charges of approximately $0.1 million in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs. The Comp
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000018/0001618835-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.